Search research articles
Contact Us
Filters
Showing results (31-40 of 103) with videos related to
Page
of 11
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease
|
November 16, 2016
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO<sup>®</sup> and OTEMTO<sup>®</sup> studies: a subgroup analysis by age
Gary T Ferguson, Jill P Karpel, Emmanuelle Clerisme-Beaty, et al.
COPD
|
September 15, 2020
COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy
Peter M A Calverley, Alberto de la Hoz, Wenqiong Xue, et al.
Respiratory Research
|
June 19, 2016
Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
Dave Singh, Mina Gaga, Olaf Schmidt, et al.
Advances in Therapy
|
June 27, 2015
Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis
Gary T Ferguson, Matjaž Fležar, Stephanie Korn, et al.
NPJ Primary Care Respiratory Medicine
|
December 5, 2020
Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies
Gary T Ferguson, François Maltais, Jill Karpel, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
January 8, 2019
Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β<sub>2</sub>-agonist via dry-powder inhalers and pressurized metered-dose inhalers
Eric T Wittbrodt, Lauren A Millette, Kristin A Evans, et al.
The European Respiratory Journal
|
June 1, 2013
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
Eric D Bateman, Gary T Ferguson, Neil Barnes, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 27, 2014
Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies
Gary T Ferguson, Gregory J Feldman, Peter Hofbauer, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
November 21, 2018
Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study
Edward M Kerwin, James F Donohue, Gary T Ferguson, et al.
NPJ Primary Care Respiratory Medicine
|
February 4, 2017
Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies
Gary T Ferguson, Jill Karpel, Nathan Bennett, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 103) with videos related to
Sort By:
Page
of 11
International Journal of Chronic Obstructive Pulmonary Disease
|
November 16, 2016
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO<sup>®</sup> and OTEMTO<sup>®</sup> studies: a subgroup analysis by age
Gary T Ferguson, Jill P Karpel, Emmanuelle Clerisme-Beaty, et al.
COPD
|
September 15, 2020
COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy
Peter M A Calverley, Alberto de la Hoz, Wenqiong Xue, et al.
Respiratory Research
|
June 19, 2016
Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
Dave Singh, Mina Gaga, Olaf Schmidt, et al.
Advances in Therapy
|
June 27, 2015
Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis
Gary T Ferguson, Matjaž Fležar, Stephanie Korn, et al.
NPJ Primary Care Respiratory Medicine
|
December 5, 2020
Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies
Gary T Ferguson, François Maltais, Jill Karpel, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
January 8, 2019
Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β<sub>2</sub>-agonist via dry-powder inhalers and pressurized metered-dose inhalers
Eric T Wittbrodt, Lauren A Millette, Kristin A Evans, et al.
The European Respiratory Journal
|
June 1, 2013
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
Eric D Bateman, Gary T Ferguson, Neil Barnes, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 27, 2014
Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies
Gary T Ferguson, Gregory J Feldman, Peter Hofbauer, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
November 21, 2018
Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study
Edward M Kerwin, James F Donohue, Gary T Ferguson, et al.
NPJ Primary Care Respiratory Medicine
|
February 4, 2017
Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies
Gary T Ferguson, Jill Karpel, Nathan Bennett, et al.
Page
of 11